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Abstract
An innovative approach for cardiac regeneration following injury is to induce endogenous 
cardiomyocyte (CM) cell cycle re-entry. In the present study, CMs from adult rat hearts were 
isolated and transfected with cel-miR-67 (control) and rno-miR-210. A significant increase in CM 
proliferation and mono-nucleation were observed in miR-210 group, in addition to a reduction in 
CM size, multi-nucleation, and cell death. When compared to control, β-catenin and Bcl-2 were 
upregulated while APC (adenomatous polyposis coli), p16, and caspase-3 were downregulated in 
miR-210 group. In silico analysis predicted cell cycle inhibitor, APC, as a direct target of miR-210 
in rodents. Moreover, compared to control, a significant increase in CM survival and proliferation 
were observed with siRNA-mediated inhibition of APC. Furthermore, miR-210 overexpressing 
C57BL/6 mice (210-TG) were used for short-term ischemia/reperfusion study, revealing smaller 
cell size, increased mono-nucleation, decreased multi-nucleation, and increased CM proliferation 
in 210-TG hearts in contrast to wild-type (NTG). Likewise, myocardial infarction (MI) was 
created in adult mice, echocardiography was performed, and the hearts were harvested for 
immunohistochemistry and molecular studies. Compared to NTG, 210-TG hearts showed a 
significant increase in CM proliferation, reduced apoptosis, upregulated angiogenesis, reduced 
infarct size, and overall improvement in cardiac function following MI. β-catenin, Bcl-2, and 
VEGF (vascular endothelial growth factor) were upregulated while APC, p16, and caspase-3 were 
downregulated in 210-TG hearts. Overall, constitutive overexpression of miR-210 rescues heart 
Correspondence to: Rafeeq P. H. Ahmed.
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00109-017-1591-8) contains 
supplementary material, which is available to authorized users.
Compliance with ethical standards All animal have been utilized in accordance with the protocol approved by the Institutional 
Animal Care and Use Committee (IACUC), and the studies have been performed in accordance with the ethical standards. The 
manuscript does not contain any clinical studies or patient data.
Conflict of interest The authors declare that they have no conflict of interest.
HHS Public Access
Author manuscript
J Mol Med (Berl). Author manuscript; available in PMC 2018 May 09.
Published in final edited form as:













function following cardiac injury in adult mice via promoting CM proliferation, cell survival, and 
angiogenesis.
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Introduction
Cardiovascular diseases (CVD) are the leading cause of death worldwide. According to the 
recent heart disease and stroke statistics report of American Heart Association, CVD-
associated global mortality represents 17.3 million deaths each year. Its medical care costs 
more than $215 billion per year in the USA alone, that is expected to raise up to $1208 
billion per year by 2030 [1]. Ischemic cardiomyopathy is one of the most common cardiac 
myopathies, originates due to inadequate oxygen and nutrient supply, resulting in 
myocardial infarction (MI). Following MI, active myocardium degenerates and is replaced 
by physiologically inactive fibrotic tissue leading to cardiac remodeling and heart failure. 
Even though several cell-based and non-cellular therapeutic strategies are under trial to treat 
ischemic heart diseases including stem cell transplantation, tissue engineering approaches, 
direct reprogramming of host fibroblasts, and mobilization of resident bone marrow cells 
[2], none of these have transitioned into routine clinical use.
At present, induction of cardiac regeneration following myocardial injury is one of the 
emerging areas of research with the potential of long-term favorable outcomes. Contrary to 
the long-held belief that the mammalian heart is a post-mitotic organ without any 
regeneration potential, recent studies in neonatal mice have shown cardiomyocytes (CMs) to 
proliferate up to day 7 after birth [3]. However, adult mammalian CMs become fully 
differentiated and lose their ability to proliferate, thereby are unable to regenerate/repair lost 
myocardium following ischemic and non-ischemic cardiac damage. Therefore, targeting 
induction of adult CM mitosis is a key therapeutic approach for cardiac regeneration. One of 
the novel strategies under extensive research is the use of microRNAs (miRs), to promote 
CM proliferation. Similar to studies using neonatal CMs [4], miRs also have the potential to 
induce adult CM cell cycle re-entry [5, 6]. MiRs are evolutionary conserved, small segments 
of ~ 22 nucleotide long non-coding eukaryotic RNAs, which regulate the expression of 
numerous genes via mRNA degradation and translational inhibition. So far, several miRs are 
documented to be involved in various cardiomyopathies leading to cardiac failure [7, 8]. Out 
of these, miR-210 was reported to be upregulated in animal models of atherosclerosis [9], 
cardiac hypertrophy, acute MI [10], and heart failure [11, 12]. Interestingly, earlier studies 
showed that intra-myocardial injection of miR-210 can improve heart function, reduces 
infarct area, prevents CM apoptosis, and induces angiogenesis post-MI in mice [13], 
suggesting miR-210 delivery might be cardioprotective during ischemic injury. Moreover, 
various broadly conserved gene targets of miR-210 have been identified, which are known to 
be associated with mitochondrial metabolism, DNA repair, cell survival, cell cycle 
progression, and angiogenesis [14]. These targets could significantly affect the development 
of major CVD, such as MI, which subsequently leads to heart failure. Notably, miR-210 has 
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been previously implicated in activation of cell proliferation [15–21] revealing its potential 
for cell cycle induction. However, there is no published report to this date, supporting the 
role of miR-210 in adult CM cell cycle re-entry. Earlier reports showed that miR-210 is a 
master hypoxamir, as it is upregulated in various cell types during hypoxia [14] under the 
influence of hypoxia inducible factor-1-alpha (HIF-1α) [22–24]. Interestingly, a recent study 
has demonstrated that hypoxia promotes hyper-activation of HIF-1α and induction of 
endogenous CM proliferation leading to cardiac regeneration, reduction in myocardial 
fibrosis, and improvement of heart function post-cardiac injury in adult mice [25].
Altogether, these studies support the possible therapeutic potential of miR-210 for induction 
of CM proliferation, cell survival and angiogenesis leading to cardiac tissue regeneration. 
Thus, there is an essential need for in-depth analysis of miR-210-mediated signaling 
pathways that could possibly unfold the basic mechanism behind the induction of CM cell 
cycle re-entry. This strategy could be a novel step for the development of a promising 
therapeutic approach to treat ischemic cardiomyopathies. In the present study, for the first 
time, we report miR-210-mediated CM proliferation under in vitro and in vivo systems, 
along with cell survival and improved angiogenesis. Thus, our proposed strategy could be 
used as an effective therapeutic approach following cardiac damage to regenerate lost 
myocardium leading to restoration of heart function.
Materials and methods
All chemicals and laboratory reagents were purchased from Sigma-Aldrich, MO unless 
otherwise mentioned. Antibodies used in the current study were obtained from Sigma-
Aldrich, MO (Rabbit anti-β-actin, Cat. A1978; rabbit anti-GAPDH, Cat. G9545; rabbit anti-
Aurora B, Cat. A5102); Santa Cruz Biotechnology, TX (Rabbit anti-cardiac troponin-I, Cat. 
sc-15368; rabbit anti-VEGF, Cat. sc-152); Abcam, MA (Rabbit anti-p16, Cat. ab51243); 
Cell Signaling Technology, MA (Rabbit anti-APC, Cat. 2504S; rabbit anti-caspase-3, Cat. 
9661S; rabbit anti-Bcl-2, Cat. 2870S; rabbit anti-β-catenin, Cat. 9562S); BD Pharmingen, 
CA (Mouse anti-Ki67, Cat. 550,609); GE Healthcare, IL (ECL anti-mouse-HRP, Cat. 
NA931V; ECL anti-rabbit-HRP, Cat. NA9340V); Life Technologies, CA (Goat anti-mouse 
Alexa fluor 488, Cat. A11029; goat anti-mouse Alexa fluor 594, Cat. A11005; goat anti-
rabbit Alexa fluor 488, Cat. A11008; goat anti-rabbit Alexa fluor 594, Cat. A11037), and 
Thermo Scientific, MA (Mouse anti-cardiac troponin-T, Cat. MA5-12960).
All experimental animals were housed and maintained at Laboratory Animal Medical 
Services (LAMS), University of Cincinnati, Ohio, USA. The animals were fed ad libitum 
standard food and were utilized in accordance with the protocol approved by the 
Institutional Animal Care and Use Committee (IACUC).
Adult rat cardiomyocyte (ARCM) isolation, transfection, and culture
Primary cultures of ventricular cardiomyocytes were obtained from 12-week-old Fisher rats. 
For the same, rats were euthanized, hearts were dissected and perfused using solution A (118 
mM NaCl, 4.8 mM KCl, 25 mM HEPES, 1.25 mM MgSO4, 1.25 mM K2HPO4, 10 mM 
glucose, 4.95 mM Taurine, 9.89 mM 2,3-Butanedione monoxime; pH −7.35). The hearts 
were then adjusted on Langendorff system and digested using digestion buffer [solution A 
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with 0.1% Bovine serum albumin (BSA), 0.05 mM CaCl2, 0.07% collagenase type II, 0.02% 
hyaluronidase type I]. Then, ventricular tissue was taken and minced in digestion buffer. The 
cell suspension was filtered using 100 μm cell strainer (BD Biosciences, CA) and the filtrate 
was centrifuged at 300 rpm for 3 min at room temperature (RT). The cell pellet was 
resuspended in solution B (solution A with 1% BSA, 0.1 mM CaCl2) and cells were allowed 
to settle under gravity. Then, the cell pellet was resuspended and seeded in DMEM/High 
glucose media (GE Healthcare, UK) containing 10% fetal bovine serum (FBS) (Fisher 
Scientific, MA) and 1% Penicillin/Streptomycin (Fisher scientific, MA). 24 h post-seeding, 
cells were transfected with rno-miR-210 mimic (50 nM) and negative control, 
Caenorhabditis elegans-specific miR, cel-miR-67 (50 nM) (Dharmacon, CO), and APC 
siRNA (siAPC) (50 nM) (Ambion, MA) using Lipofectamine RNAiMAX reagent (Life 
Technologies, CA) according to the manufacturer’s instructions. 24 h following transfection, 
media was removed and fresh culture media containing 0.5% EdU (5-ethynyl-2′-
deoxyuridine) (Life Technologies, CA) was added. Cells were cultured for 1 week post-
transfection and used for further studies. Likewise, in another setup, seeded cells were 
transfected using siUBC (Ubiquitin-C siRNA) (50 nM) (Ambion, MA) and transfection 
control mimic tagged with Dy547 (50 nM) (Dharmacon, CO), and transfection efficiency 
was calculated at day 4 post transfection.
Immunocytochemistry (IC)
One week post transfection, CM cultures were fixed with 4% paraformaldehyde in PBS 
(Phosphate buffered saline) (pH 7.4) for 20 min followed by permeabilization using 0.1% 
Triton X-100 for 15 min. Cells were washed with PBS and blocked with CAS-Block (Life 
Technologies, CA) for 1 h at RT. Cells were then incubated with primary antibody in CAS-
Block overnight at 4 °C. Cells were then washed with PBS followed by incubation with 
secondary antibody in CAS-Block for 1 h at RT. Cells were again washed with PBS and 
incubated with nuclear stain DAPI (4′,6-diamidino-2-phenylindole) for 10 min. Imaging 
was done under a fluorescence microscope (Olympus).
Assessment of CM proliferation and apoptosis
Post one week following transfection, CM number, size, nucleation, EdU and Ki67 labeling 
were examined. To analyze CM number, CMs were labeled with cardiac-specific Troponin-I 
(TnI) primary antibody followed by a secondary antibody linked with Alexa fluor, and 
DAPI. TnI positive (TnI+) CMs and respective nuclei were counted under a fluorescence 
microscope. For cell size, individual TnI+ CM area was quantified using ImageJ analysis 
program (NIH, MD). EdU labeling was performed using EdU imaging kit (Invitrogen, CA) 
according to manufacturer protocol. Similarly, apoptosis in CM culture was analyzed using 
TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) detection kit 
(Roche, IN).
MiR-210 overexpressing mice model
MiR-210 overexpressing transgenic (210-TG) mice were generated at the University of 
Cincinnati Transgenic core using the C57BL/6 mouse strain. Briefly, precursor miR-210 
along with H1 promoter (HmiR0167-MR01 vector from GeneCopoeia, MD) was amplified 
and cloned into pShuttle vector (Stratagene, CA) using restriction enzymes Not1 and Sal1. 
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Amplified vector was digested, purified, and used for microinjection into the pro-nuclei of 
single-cell embryos derived from superovulated C57BL/6 females. The surviving embryos 
were implanted into foster female mice. 210-TG and non-transgenic wild-type (NTG) mice 
were identified by genotyping of the tail genomic DNA via PCR for custom designed 
primers (Table S1). To examine the possible tumorigenic effect of miR-210 overexpression 
on major organs, we compared the size of different organs via measuring organ weight to 
body weight ratios in one-year-old NTG and 210-TG mice (N = 8) (Fig. S3A). Additionally, 
we evaluated the expression profile of cell proliferation marker, Aurora B via qPCR, in the 
lung, liver, and kidney in one-year-old NTG and 210-TG mice (Fig. S3B) (N = 4).
Target analysis and confirmation
Using in silico analysis tool, APC was predicted to be a direct conserved target having 
miR-210 binding sites on its 3′UTR (3′ untranslated region) in mouse and rat. Additionally, 
to validate the target sequence in rodents, we performed dual luciferase assay in adult rat 
CMs which is described in detail below. In another parallel experiment, APC was 
knockdown in ARCMs via siAPC and was examined for EdU, Ki67, and TUNEL labeling.
Luciferase assay
Rat APC 3′UTR with miR-210 target sequence was retrieved from NCBI (https://
www.ncbi.nlm.nih.gov/gene/). Target sequence was PCR amplified by using specific primers 
(Forward; 5′ GTTGTTGAATTCAGGAAAACAAAGTGTGGGCAG; Reverse 5′ 
GTTGTTACTAGTCGCTGCTTTTCCTAGG GCTT) and cloned into dual luciferase vector 
(GeneCopoeia) designated as WT 3′UTR-APC. For mutagenesis assay, seed sequence 
mutation in the miR-210 binding site of APC-3′UTR was created by site directed 
mutagenesis and vector designated as MT 3′UTR-APC. Afterward, adult Fisher rat CMs 
were isolated and seeded in 80% confluency in a 24-well plate with 500 μl of culture 
medium [DMEM/High glucose media (GE Healthcare, UK) containing 10% FBS (Fisher 
scientific, MA) and 1% Penicillin/Streptomycin (Fisher scientific, MA)]. Post overnight 
culture, CMs were cotransfected with 300 ng of WT 3′UTR-APC and 50 nM rno-miR-210 
mimic using Lipofectamine 2000 (Invitrogen), according to the manufacturer’s 
recommendations. Likewise, for mutagenesis assay, CMs were co-transfected with 300 ng of 
MT 3′UTR-APC and 50 nM rno-miR-210 mimic. Cel-miR-67 mimic (50 nM) serves as a 
control. Luciferase assay was performed after 36 h post-transfection. For the same, cell 
lysates were prepared by using passive lysis buffer and then assayed for luciferase activity 
using the Luc-Pair Duo-Luciferase assay kit 2.0 (GeneCopoeia). Luciferase activity of the 
fusion proteins was measured with a Microplate Luminometer and normalized to the activity 
of Renilla luciferase.
RNA extraction and real-time PCR
Total RNA was extracted from mouse hearts or cultured cells using Trizol reagent in 
accordance with the manufacturer protocol (Invitrogen, CA). In short, heart or other organ 
samples were homogenized in 1 ml Trizol reagent followed by 5-min incubation at RT. 0.2 
ml chloroform was added followed by 15-sec shaking and further incubated for 3 min at RT. 
Samples were centrifuged at 12000×g for 15 min at 4 °C. The aqueous phase was transferred 
to a new tube and 0.5 ml isopropanol was added. Samples were then incubated at RT for 10 
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min followed by centrifugation at 1200×g for 10 min at 4 °C. RNA pellet was separated, 
washed with 1 ml of 75% ethanol and was centrifuged at 7500×g for 5 min at 4 °C. Wash 
was discarded, RNA pellet was air-dried for 10–30 min at RT and dissolved in 50 μl of 
RNase-free water. RNA concentration was estimated using Nanodrop and purity was 
checked by A260/280 ratio > 1.6. Purified RNA was further used for qRT-PCR of miR-210 
using miScript Primer assay kit (Qiagen, MD) according to manufacturer recommended 
procedure. RT-PCR was performed using Bio-Rad Real-Time PCR Detection System. 
Results were normalized with internal control and analyzed via comparative Ct method. 
Results were also examined using PCR product via 1.5% agarose gel electrophoresis.
Echocardiography
Indices of left ventricular function and chamber dimensions during systole and diastole were 
examined via echocardiography (Echo), performed just prior to surgery and then 4 weeks 
following MI with a Vevo 2100 Imaging digital ultrasound system (VisualSonics) using a 
22–55 MHz (MS550D) for adult mice. Prior to echocardiography, mice anesthetized with 
oxygen mixed with isoflurane (2–2.5%) at a heart rate of ~ 400 beats/min. Mice chest hairs 
were shaved and the animals were then placed on a warm platform in supine position. Data 
acquisition was initiated with the parasternal cardiac long axis view followed by a transition 
to the short axis view, at the level of mid-papillary muscles. Measurements were obtained 
from short axis M-mode images and graphically represented as % LVEF (left ventricular 
ejection fraction) and % LVFS (left ventricular fraction shortening).
Ischemia/reperfusion (I/R) injury mice model
The ischemic injury was created in 12-week-old miR-210 overexpressing (210-TG) and 
wild-type (NTG) mice by 30-min temporary LAD (left anterior descending) artery ligation 
followed by reperfusion. Post-surgery, EdU (5-ethynyl-2′-deoxyuridine) was administrated 
in-traperitoneally (i.p.) at a dose of 500 μg/100 μl PBS on alternate days up to day 12. On 
day 14, echocardiography was performed and animals were euthanized. Finally, CMs were 
isolated, seeded on a culture dish, and stained for EdU, TnI, and DAPI followed by further 
analysis.
Myocardial infarction (MI)
Myocardial infarction was created in 12-week-old 210-TG and wild-type (NTG) mice via 
permanent ligation of left anterior descending (LAD) coronary artery, following which EdU 
was administrated intraperitoneal at a dose of 500 μg/100 μl PBS on alternate days up to day 
12. For long-term studies 4 weeks post LAD, echocardiography was performed, and animals 
were euthanized to collect hearts. The hearts were fixed, embedded in paraffin blocks for 
sectioning followed by staining with Masson’s Trichrome or hematoxylin/eosin to assess 
percent attenuation of infarct size. In addition, heart sections were used for 
immunohistochemistry (IHC) analysis. Heart samples were also saved for molecular studies.
Histological examination and immunohistochemistry
Prior to isolation, the hearts were arrested in diastole with 1 M KCl and perfused and fixed 
in 10% buffered formalin solution overnight at 4 °C. Tissue samples were embedded in 
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paraffin blocks followed by sectioning. Formalin fixed tissue slides were de-paraffinized via 
incubation at 65 °C for 30 min followed by immediately dissolving paraffin in xylene and 
re-hydrating through sequential 5-min incubations in graded ethanol (100, 90, and 80%) and 
water. Antigen retrieval was performed via heating the slides in a pressure cooker in 0.1 M 
citrate buffer (pH 6.0) for 3 min followed by cooling for 45 min. Tissue sections were 
blocked with CAS-Block (Invitrogen, CA) for 1 h, incubated with primary antibody against 
analyzing antigen for 1–3 h at 37 °C followed by incubation with appropriate secondary 
antibody linked with Alexa fluor for 1 h at 37 °C. Slides were subsequently treated with 
DAPI for 10 min, washed with PBS, and mounted with Fluoromount-G (SouthernBiotech, 
AL). Slides were examined using a confocal microscope (Olympus). Cell area/size was 
defined by staining of cardiac tissue with TnI and wheat germ agglutinin (WGA) 
(Invitrogen, CA). EdU labeling and apoptotic cell death were determined via EdU imaging 
kit (Invitrogen, CA) and TUNEL kit (Roche, IN) respectively, according to manufacturer’s 
instructions. CMs undergoing mitosis were examined via anti-Aurora B (cell cytokinesis 
marker) staining. To analyze angiogenesis, blood vessels were stained using anti-smooth 
muscle actin (Sigma, MO) and VWF (von Willebrand factor) (Dako, CA) antibodies.
SDS gel electrophoresis and Western blot
Cell lysate preparation—Cell cultures were washed with PBS and mechanically 
detached from the surface using a cell scraper or mild trypsin treatment. Cell suspensions 
were then collected in a microcentrifuge tube and centrifuged at 5000 rpm for 5 min. Pellets 
were resuspended in 100 μl of 1X RIPA buffer and incubated at 4 °C for 1 h. 5× SDS sample 
buffer (60 mM Tris-Cl pH 6.8, 2.5% Glycerol, 2% SDS, 0.1% Bromophenol Blue) was 
added and boiled for 15 min followed by centrifugation at 13000 rpm for 15 min at 4 °C. 
The supernatants containing the lysate proteins were collected and stored at −20 °C for 
further use.
Tissue lysate preparation—Mice hearts were collected, perfused with PBS and 
homogenized in Laemmli buffer with β-mercaptoethanol followed by immediate boiling in 
boiling water bath for 20 min. Subsequently, the lysate was centrifuged at 12000×g for 30 
min at 4 °C and the supernatant was stored at −80 °C until use.
Protein content was estimated using Pierce 660 nm reagent kit (Thermo Scientific, MA). 
Linear slab gel electrophoresis under the denaturing condition (in the presence of 0.1% 
SDS) was performed. Protein samples were stacked and were electrophoresed using 10–12% 
polyacrylamide gel (Invitrogen, CA) and running buffer (containing 0.025 M Tris-base, 
0.192 M glycine pH 8.3, and 0.1% SDS) in Novex apparatus (Life Technologies, CA). 
Standard molecular weight marker was electrophoresed alongside to observe the subunit size 
of the analyzed protein. Electrophoresed protein samples were electroblotted onto PVDF 
membrane by applying 0.8 mA/h current in a wet transfer unit (BioRad, CA) and were 
detected using anti-rabbit or anti-mouse antibodies conjugated with horseradish peroxidase 
(HRP). Then, blots were treated with SuperSignal W. Femto max sensitivity (Thermo Fisher, 
MA) enhanced chemiluminescence (ECL) substrate. Blot was kept in a cassette: a film 
exposed to it and developed to visualize the protein bands.
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To study angiogenesis in mice, aortic ring assay was performed according to published 
protocol [26] with few changes. In short, 12-week-old 210-TG and NTG mice were 
euthanized, and aorta, located along with spine, were dissected, cleaned in Opti-MEM 
media, and cut into rings of 1 mm width. Rings were serum starved overnight in Opti-MEM 
at 37 °C and 5% CO2 followed by embedding in Matrigel matrix (Sigma, MO). Rings were 
fed with 199-media (Sigma, MO) containing 2.5% FBS, 1% Penicillin/Streptomycin. In 
addition, aortic rings from NTG mice were also treated with same media supplemented with 
purified VEGF (Vascular endothelial growth factor) (30 ng/ml) and considered as a positive 
control for neovascularization. Post 1 week, rings were fixed with 4% paraformaldehyde in 
PBS for 20 min followed by washing with PBS. Imaging was done under bright field and 
numbers of microvessel sprouts were counted in each aortic ring.
Statistical analysis
Statistical analysis was performed using ANOVA and Student’s t test. All values were 
expressed as mean ± SEM. P < 0.05 was considered statistically significant.
Results
MiR-210 induces proliferation in ARCM
MiR-210 has already been shown to induce proliferation in various cell lines [15–18, 21]; 
however, there is no report to this date that reflects its effect on adult CMs mitosis. To 
investigate the proliferative potential of miR-210, 12-week-old rat CMs were isolated and 
transfected with cel-miR-67 (control) and rno-miR-210 mimic (Fig. 1a). One week post-
transfection, cells were fixed, permeabilized, and stained for cardiac-specific TnI, and cell 
proliferation markers, EdU and Ki67. As compared to control, miR-210 transfected group 
showed a twofold increase in cell number (Fig. 1b, e) while cell size was significantly 
reduced (Fig. 1b, f). Moreover, control group CMs showed intact and well-organized 
myofibrils which were found to be disorganized in miR-210 transfected cells, suggesting 
dedifferentiation of these CMs while undergoing proliferation (Fig. 1b). Likewise, miR-210-
transfected CMs showed a significant increase in mono-nucleation while multi-nucleation 
was decreased (Fig. 1g). In contrast to control, miR-210 group represented a fourfold 
increase in EdU+ (Fig. 1c, h) and Ki67+ (Fig. 1d, i) cells, suggesting CM proliferation. 
Additionally, for validation of our transfection protocol, transfection efficiency was analyzed 
using cel-miR-67 mimic (as control), siUBC (Ubiquitin-C siRNA), and Dy547 mimic, and 
we observed ~ 65–73% transfection efficiency in ARCMs (Fig. S1).
MiR-210 reduces cell death in ARCM
MiR-210 is also documented to reduce CM apoptosis in mice post-cardiac injury [13]. Thus, 
to examine the antiapoptotic effect of miR-210 in adult CMs in vitro, we analyzed the rno-
miR-210 transfected ARCM post 1 week of transfection. In contrast to cel-miR-67 
transfected control, miR-210 group showed threefold reductions in TUNEL positive cells, 
suggesting a significant decrease in CM apoptosis (Fig. 2a–b). In addition, a twofold 
upregulation of cell survival factor Bcl-2 and threefold downregulation of apoptosis marker 
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cleaved caspase-3 to caspase-3 ratio were seen in miR-210 group that further supports the 
pro-survival role of miR-210 in ARCM (Fig. 2c).
APC is the direct target of miR-210
APC is a part of canonical Wnt signaling pathway that negatively regulates cell cycle 
progression via promoting β-catenin degradation. In silico analysis predicted binding sites 
for miR-210 on 3′UTR region of APC gene of the mouse, and rat (Fig. 3a). To validate this 
experimentally, dual luciferase assay was performed in ARCMs, and we found a twofold 
downregulation in luciferase activity in miR-210 + WT 3′UTR-APC group containing a 
normal 3′UTR target sequence as compared to miR-210 + MT 3′UTR-APC group 
containing a mutated 3′UTR target site (Fig. 3b), suggesting miR-210-mediated inhibition 
of APC. In a parallel experiment, compared to cel-miR-67 (control), miR-210 transfected 
CMs showed a significant downregulation of cell cycle inhibitors like APC and p16, while 
cell cycle activator β-catenin was upregulated (Fig. 3c). Further, to evaluate the effect of 
miR-210 mediated inhibition of APC on CM proliferation, ARCMs were isolated and 
transfected with cel-miR-67 (control), miR-210, and siAPC individually. One week post 
transfection, cultured cells were fixed, permeabilized, and stained for TnI, EdU, and Ki67. 
As compared to control, miR-210 and siAPC transfected groups showed threefold and 
twofold increase in EdU+ and Ki67+ cells respectively (Fig. 3d–e, f–g), suggesting 
induction of CM proliferation in both the groups when compared to control. Moreover, 
miR-210 and siAPC transfected CMs also showed a threefold decrease in TUNEL labeling 
(Fig. 3h–i), indicating a significant reduction in cell death in these groups.
MiR-210 overexpression promotes CM proliferation in adult mice post-ischemic injury
To analyze the effect of miR-210 under in vivo system, we generated miR-210 
overexpressing transgenic mice (210-TG) using C57BL/6 strain (Fig. 4a). Genotyping 
confirmed the upregulation of miR-210 in 210-TG mice as compared to NTG (non-
transgenic/wild type) (Fig. 4b). In addition, qPCR data of different organs (spleen, heart, 
lung, skeletal muscle, kidney) and blood samples showed significant upregulation of 
miR-210 expression in 210-TG as compared to NTG (Fig. 4c–d). Moreover, to study the 
effect of miR-210 overexpression following cardiac injury, 12-week-old mice were subjected 
to 30-min LAD ligation followed by permanent reperfusion for 2 weeks [Ischemia/
reperfusion (I/R) model] (Fig. 4e). EdU was administered on alternate days following 
surgery until day 12. The hearts were dissected, and CMs were isolated and seeded for 24 h. 
Immunocytochemistry and quantification of EdU labeling showed a significant increase in 
EdU+ CMs in 210-TG hearts post I/R injury (Fig. 4f–g), indicating CM proliferation. 
However, CMs from baseline hearts were lacking EdU labeling, suggesting the absence of 
CM proliferation in these mice (Fig. S2). In contrast to NTG, 210-TG hearts showed a 
significant increase in mono-nucleated CMs while multi-nucleation was decreased following 
I/R injury (Fig. 4h). Likewise, contrary to NTG, CM size decreased significantly in 210-TG 
hearts at baseline. In addition, compared to basal groups, CM size further decreased 
following cardiac injury. However, we observed no significant difference in CM size 
between NTG and 210-TG hearts post I/R (Fig. 4i). To examine the possible tumorigenic 
effect of overexpressed miR-210, we compared the body weight as well as size of different 
organs via measuring organ weight to body weight ratios in 1-year-old NTG and 210-TG 
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mice (N = 8), which were found to be similar for the spleen, lung, liver, kidney, and brain 
(Fig. S3A). In continuation, we also examined the expression profile of cell proliferation 
marker, Aurora B via qPCR, that was also non-significant in the lung, liver, and kidney in 1-
year-old NTG and 210-TG mice (Fig. S3B). These observations clearly indicate that 
although miR-210 promotes cell proliferation and angiogenesis in injured heart tissue, it did 
not show any tumorigenic sign in other major organs. Thus, present data supports the non-
carcinogenic behavior of miR-210 therapy in 1-year-old 210-TG mice.
MiR-210 overexpression rescues heart function in adult mice following MI
To evaluate the effect of miR-210 on adult mice cardiac function post injury, myocardial 
infarction was created by permanent LAD artery ligation in 12-week-old 210-TG and wild-
type (NTG) mice. EdU was administered on alternate days up to day 12. Prior to surgery, 
and 4 weeks after MI, echocardiography was performed. Animals were then euthanized, and 
hearts were collected for histopathological and molecular analysis (Fig. 5a). Masson’s 
Trichrome stained tissue sections were used to measure infarct area, showing a significant 
decrease in infarct size in 210-TG hearts as compared to NTG (Fig. 5b, e). At baseline and 
post-MI, 210-TG hearts expressed sixfold upregulated levels of miR-210 (Fig. 5d). Heart 
weight to body weight ratio remains unaffected in both groups at baseline as well as 
following MI (Fig. 5f). Echocardiographic analysis showed a normal heart function at 
baseline in both groups. However, post-MI, heart activity, as represented by percent LVEF 
and LVFS, was significantly restored in 210-TG hearts as compared to NTG (Fig. 5c, g–h).
MiR-210 overexpression promotes CM proliferation in adult mice post-MI
APC is a member of Wnt pathway that forms a complex with other members to degrade β-
catenin leading to inhibition of cell mitosis. In other words, APC negatively regulates cell 
cycle reentry. Thus, to evaluate the proliferative potential of miR-210 under in vivo system, 
Wnt signaling pathway was explored. Four weeks post-MI, mice were euthanized and hearts 
were collected for further studies. Immunohistochemistry and quantification of WGA 
stained peri-infarct zone indicated a significant decrease in CM size in 210-TG hearts as 
compared to NTG (Fig. 6a, d). Immunostaining and quantification of EdU-stained CMs at 
peri-infarct zone demonstrated a fourfold increase in EdU+ CMs in 210-TG hearts (Fig. 6b, 
e), suggesting CM proliferation. Additionally, troponin-T (TnT) and Aurora B specific 
immunostaining showed a fivefold increase of Aurora B+ CMs at the peri-infarct area in 
210-TG hearts, indicating significant CM cell cycle re-entry (Fig. 6c, f). Western blots and 
densitometry showed nonsignificant changes in APC, β-catenin and p16 at baseline (Fig. 
6g). However, following MI, twofold downregulation in APC and p16 expression were 
observed in 210-TG hearts as compared to NTG (Fig. 6h). In addition, 210-TG mice showed 
significant upregulation of β-catenin level (Fig. 6h), supporting CM cell cycle progression.
MiR-210 overexpression reduces cell death and promotes angiogenesis in adult mice 
following MI
Heart sections from 4-week post-MI animals were examined for apoptosis and angiogenesis. 
Immunohistochemistry and quantification of TUNEL+ CMs at peri-infarct zone showed a 
twofold decrease in apoptotic CMs in 210-TG hearts (Fig. 7a–b). Western blots and 
densitometric analysis illustrated the non-significant change in Bcl-2 and caspase-3 
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expression at baseline (Fig. 7c). However, significant upregulation in Bcl-2 and twofold 
downregulation in caspase-3 was observed in 210-TG hearts post-MI (Fig. 7d), suggesting 
reduced cell death. Moreover, 210-TG hearts showed a twofold increase in blood vessel 
density at the peri-infarct zone, indicating upregulation of angiogenesis (Fig. 8a–b). 
Likewise, immunoblotting showed unaltered levels of angiogenic factor VEGF at baseline. 
Though, following MI, twofold upregulation in VEGF expression was observed in 210-TG 
hearts as compared to NTG (Fig. 8c). In a parallel experiment, angiogenic potential was 
further assessed in different mice groups via aortic ring assay, showing fourfold increment in 
aortic microvessel sprout formation, representing upregulated neovascularization, in 210-TG 
and NTGVEGF (VEGF-treated NTG) groups as compared to NTG (Fig. 8d–e). These 
observations clearly suggest the higher angiogenic potential of miR-210. In addition, 
HIF-1α expression was slightly increased in the 210-TG hearts at baseline and following MI 
(Fig. S4).
Discussion
For a long time, the mammalian heart was presumed to be a post-mitotic organ as CMs 
undergo cell cycle arrest soon after birth [27–29]. However, recent studies have shown that 
adult mammalian heart has a small fraction of cycling CMs with limited proliferative 
capacity, though these are insufficient to rescue heart function following cardiac injury [30]. 
Therefore, there is a pressing need to develop novel therapeutic approaches to promote 
cardiac regeneration. In contrast to adult mammals, newts, zebrafish, and neonate mice 
(before day 7 after birth) can successfully regenerate their hearts post injury via endogenous 
CM mitosis [31–33]. Based on this, it is a promising strategy to induce cell cycle re-entry of 
preexisting CMs, surrounding the site of injury. Following this approach, there are few 
studies that have attempted to induce CM proliferation to regenerate injured myocardial 
tissue in adult animal models [34, 35]. Likewise, some recent reports have also documented 
the inherent potential of certain miRNAs that can induce proliferation in terminally 
differentiated adult CMs [5, 34]. Similarly, earlier studies indicate that master 
hypoxamiR-210 (miR-210) has cell proliferative potential [15, 17–19, 21]. On the contrary, 
miR-210 knockdown using siRNA could lead to cell cycle arrest [16, 21]. However, to this 
date, there is no report on miR-210 mediated induction of adult CM mitosis. Hence, to 
explore miR-210-associated effect and underlying mechanism on CM proliferation, we 
proposed the current study, which has a potential therapeutic application for ischemic heart 
injuries like MI. According to our present study, miR-210 is one of the unique candidate 
miRNAs which can promote adult CM proliferation, cell survival, and cardiac angiogenesis 
simultaneously, following myocardial injury. Altogether, these favorable key characteristics 
of miR-210 can reduce pathological remodeling of the scarred tissue and regenerate new 
functional myocardium leading to the significant recovery of impaired heart function.
In order to examine the effect of miR-210 on adult CMs, we transfected ARCMs with cel-
miR-67 (negative control) and rno-miR-210 mimics. One week post transfection, cells were 
analyzed for proliferation and apoptosis. Compared to control group, miR-210 
overexpression induced adult CM proliferation as indicated by significant increase in cell 
number, smaller cell size, and higher EdU+ and Ki67+ cells. Moreover, contrary to control, 
miR-210 transfected CMs illustrated disorganized myofibrils, supporting their de-
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differentiated morphology that is another key characteristic of proliferating CMs. 
Interestingly, a significant increase in smaller mono-nucleated CMs was seen in miR-210 
group, while the number of multi-nucleated CMs was reduced. This observation supports 
CM cell cycle re-entry resulting in proliferation, and reduced mitotic catastrophe-induced 
cell death as reported by earlier studies [36]. In continuation, we observed fourfold 
increment in EdU and Ki67 labeling in miR-210 transfected CMs as compared to control, 
while the cell number was almost double in miR-210 group. One probable rationale behind 
such robust increase in cell number in miR-210-transfected population could be due to a 
higher rate of mitosis and reduced cell death. Thus, to examine this hypothesis, TUNEL 
assay was performed, and we observed a threefold decrease in TUNEL+ CMs, favoring a 
significant increase in CM survival in miR-210 transfected group. In addition, upregulation 
of survival factor Bcl-2 and downregulation of apoptosis marker caspase-3 in miR-210 
group provided further support for an anti-apoptotic effect of miR-210. The elevated 
caspase-3 expression is known for activation of signaling pathways leading to cell death 
[37], and in addition, is also associated with CM hypertrophy [38]. Similarly, our results also 
show downregulation of caspase-3 and smaller CM size in miR-210 group. Furthermore, we 
identified APC, an antiproliferative gene, as a direct target of miR-210, via in-silico tools. In 
addition, the miR-210 binding site was found to be conserved on 3′UTR of APC gene in the 
rat and mouse. Similar to our rodent experiments, recent studies have identified regulation of 
APC by hsa-miR-210 in human [39]. Furthermore, miR-210-mediated downregulation of 
APC was validated via dual luciferase assay performed in adult rat CMs. APC is a member 
of canonical Wnt signaling pathway that negatively regulates cell cycle progression via 
promoting degradation of cell cycle activator, β-catenin. Interestingly, β-catenin has been 
directly implicated in CM proliferation and normal ventricular maturation [40]. Conversely, 
in our study, miR-210 promotes APC inhibition to induce CM cell cycle reentry. 
Additionally, APC knockdown using siAPC also resulted in a significant increase in CM 
proliferation. Similar to miR-210 group, siAPC also showed an anti-apoptotic effect on 
CMs, suggesting shared downstream signaling in both the groups. Moreover, cell cycle 
inhibitor p16 was downregulated in miR-210 group that further favors CM mitosis, as p16 is 
known to inhibit cyclin-dependent kinases (CDK2/4/6) thereby blocking cell cycle 
progression from G1 to S phase [41].
Furthermore, we validated our in vitro observations in an in vivo system, by generating the 
first miR-210 overexpressing transgenic mice model (210-TG). We created myocardial 
injury via LAD ligation in wildtype and 210-TG animals, to evaluate the impact of 
constitutive overexpression of miR-210 on infarct size, preservation of cardiac function, 
endogenous CM proliferation, and survival. To test these objectives, foremost, ischemia/
reperfusion (I/R) mice model was used as a short-term cardiac damage (acute injury) 
prototype, and resident CM proliferation was analyzed post 2 weeks of surgery. Contrary to 
NTG, 210-TG hearts showed an increase in CM proliferation as reflected by an upregulation 
in EdU labeling, smaller cell size, and a higher number of mono-nucleated CMs. A 
significant decrease in CM multi-nucleation in miR-210 hearts at baseline as well as post-
I/R injury supports a reduction in mitotic catastrophe promoted cell death [36]. Comparable 
results were seen in permanent LAD ligation (MI) mice model that was utilized as a long-
term cardiac damage (chronic injury) prototype. In these mice, miR-210 overexpression in 
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210-TG hearts resulted in an induction of CM proliferation as revealed by smaller cell size, 
and significant elevation of EdU+ and Aurora B+ CMs at border zone of injury. 
Additionally, similar to in vitro studies, 210-TG hearts showed downregulation of APC, 
supporting the role of Wnt signaling pathway that directly controls cell cycle progression. 
Here in these animals, inhibition of APC-induced upregulation of β-catenin could force 
resident CM cell cycle re-entry. Similar supporting results were also reported by earlier 
studies stating APC deletion promotes CMs proliferation in mice heart [40]. Moreover, 
downregulation of cell cycle inhibitor p16 in 210-TG hearts further favors CM mitosis [41]. 
Thus, both our in vitro and in vivo studies clearly point towards the in-built potential of 
miR-210 to induce CM proliferation. Furthermore, decrease in the number of TUNEL+ 
CMs, upregulation of Bcl-2, and downregulation of caspase-3 in 210-TG hearts endorse 
miR-210-mediated CM survival. Interestingly, following MI, miR-210 overexpression also 
promotes angiogenesis in 210-TG hearts, as indicated by higher blood vessel density and 
upregulated angiogenic marker VEGF. Together with endogenous CM proliferation, 
infarcted myocardial revascularization is also crucial for cardiac repair, as VEGF-induced 
angiogenesis plays a key role in the healing of ischemic scar [42]. In a supporting 
experiment, the elevated angiogenic potential of miR-210 was further confirmed by aortic 
ring assay, showing upregulation of aortic microvessel outgrowths, indicating upregulated 
neovascularization in aortic ring culture of 210-TG mice. Above stated anti-apoptotic and 
proangiogenic properties of miR-210 are in accordance with other documented studies in 
adult mice post-cardiac injury [13]. In addition, HIF-1α expression was slightly increased in 
the 210-TG heart following an injury along with an increase in CM proliferation which is 
also supported by earlier reports [25].
Finally, following cardiac injury, miR-210-mediated effects like endogenous CM 
proliferation, cell survival, and angiogenesis resulted in myocardial tissue regeneration. This 
idea is evidently demonstrated by our results showing a substantial decline in infarct size in 
210-TG hearts post-MI. Eventually, all these events lead to a noteworthy restoration of heart 
function post-MI in 210-TG mice as evidently reflected by a significant improvement in 
LVEF and LVFS. Moreover, contrary to other reports showing miR-210 involvement in 
cancer progression [43], we did not observe any skin outgrowth, change in body weight, and 
size of major organs in 210-TG mice. In addition, there was no abnormal cell cycle activity, 
as suggested by similar expression of cytokinesis marker, Aurora B in the lung, liver, and 
kidney in 210-TG mice. These observations in one-year-old 210-TG mice, that are 
comparable to ~ 40 year age of its human counterpart [44], clearly suggest the non-
tumorigenic effect of miR-210 overexpression in these mice at least up until one year. 
However, we did not carry out any follow-up studies post-one year to determine if there is 
any difference in long-term survival or the potential to form tumors during later stages in 
life.
Altogether, these results clearly define the cardioprotective role of miR-210. Thus, 
constitutive overexpression of miR-210 rescues cardiac function post-MI via promoting CM 
proliferation, cell survival, and angiogenesis. Thereby, the current study suggests the 
inherent potential of miR-210 as an excellent candidate for rescuing heart function post-
cardiac injury, which can be translated into the development of a novel therapeutic regime 
for ischemic heart disease.
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• MiRNA-210 transfected adult rat CMs show proliferation and reduced cell 
death in vitro.
• Cell cycle inhibitor APC is a target of miR-210.
• MiR-210 overexpressing (210-TG) mouse hearts show CMs cell cycle re-
entry and survival post myocardial injury.
• 210-TG mice show significant neovascularization and angiogenic potential 
post myocardial infarction.
• 210-TG hearts show reduced infarct size following ischemic injury.
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MiR-210 induces proliferation of ARCM. a Experimental design workflow illustrating CM 
isolation, transfection with cel-miR-67 (control) and rno-miR-210 mimic followed by 1-
week culture under controlled conditions. Cells were then fixed, permeabilized, and utilized 
for further analysis such as cell proliferation and apoptosis. b–d Representative 
immunostained images of adult rat CMs, post 1 week of cel-miR-67 and miR-210 
transfection for cardiac-specific Troponin I (TnI), stained as green, and proliferation markers 
EdU and Ki67, stained as red (indicated by arrowheads). Cell nuclei were counterstained 
with DAPI (blue). Panels (yellow) are representing respective enlarged sections. e–g 
Quantification of the total count of TnI+ CMs, nucleation, and cell size showing a 
significant increase in CM number and a smaller cell size in miR-210 group. A significant 
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increase was also seen in mono-nucleated CMs while multi-nucleation was reduced in 
miR-210 group. h–i Quantification of EdU and Ki67 labeled CMs indicating CM 
proliferation in miR-210 group. N = 4. *P < 0.05 vs Control
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MiR-210 promotes survival of ARCM. a Immunostaining of ARCM, post 1 week of 
miR-210 and cel-miR-67 transfection, for TnI (green) and cell apoptosis marker TUNEL 
(red; indicated by arrowheads). Cell nuclei were counterstained with DAPI (blue). b 
Quantification of apoptotic TUNEL+ nuclei showing a significant decline in CM death in 
miR-210 group. c Western blot analysis in 12-week-old rat CMs, post 1 week of cel-miR-67 
and rno-miR-210 mimic transfection, showing protein expression levels of cell survival 
factor Bcl-2 and apoptosis marker cleaved caspase-3 to caspase-3 ratio. Densitometry 
representation of respective blots in fold change expression normalized by β-actin as a 
loading control, indicating Bcl-2 upregulation and caspase-3 downregulation in miR-210 
group. For all studies N = 4. *P < 0.05 vs Control
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APC is a conserved target of miR-210. a In silico analysis for miR-210 target prediction 
using Findtar3 and RNAhybrid 2.2 tools showing complementarity of the miR-210 sequence 
to 3′UTR region of APC gene in rat and mouse. b Dual luciferase assay performed in adult 
rat CMs, and quantitative analysis showing a significant downregulation in luciferase 
activity in miR-210 + WT 3′UTR-APC group containing a normal 3′UTR target sequence 
as compared to miR-210 + MT 3′UTR-APC group containing a mutated 3′UTR target site. 
Here, cel-miR-67 mimic serves as a control. c Western blot analysis showing fold change 
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expression levels of APC, β-catenin, and p16 in cel-miR-67 (Control) and miR-210 
transfected ARCM. Respective densitometry using β-actin as a loading control, showing 
downregulation of APC and p16, and up-regulation of β-catenin in miR-210 group. d, f, h 
Immunostaining of ARCMs, post 1 week of cel-miR-67 (Control), miR-210 and siAPC 
transfection for TnI (green), EdU (red), Ki67 (red), and TUNEL (red). Cell nuclei were 
counterstained with DAPI (blue). e, g, i Quantification of EdU+, Ki67+, and TUNEL+ CMs, 
indicating an increase in CM proliferation and a decrease in apoptosis in miR-210 and 
siAPC transfected groups as compared to control. For all studies N = 4. *P < 0.05 vs Control
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MiR-210 overexpression promotes CM proliferation in I/R injury mice model. a MiR-210 
overexpressing transgenic (210-TG) mice were generated using C57BL/6 strain. 210-TG 
construct was designed to have an H1 promoter, precursor miR-210 cDNA, and SV40 poly 
A cassette at 3′ end. Precursor miR-210 along with H1 promoter was amplified and cloned 
into pShuttle vector using restriction enzymes Not1 and Sal1. Amplified vector was 
digested, purified, and used for microinjection into the pronuclei of single-cell embryos 
derived from superovulated C57BL/6 females. The surviving embryos were implanted into 
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foster female mice. b Genotyping of mice tail genomic DNA via PCR using custom 
designed primers for miR-210, showing miR-210 transgenic (210-TG; lane 4) and non-
transgenic (NTG; lane 3). GAPDH was used as internal control. c qPCR results showing 
miR-210 expression in different organs such as the spleen, heart, lung, skeletal muscle 
(SkM), liver, kidney, and blood of 210-TG and NTG mice. d Quantification ofmiR-210 
expression by qPCR showing miR-210 overexpression in 210-TG mice hearts. e Schematic 
representation of 12-week-old mice subjected to LAD ligation for 30 min followed by 
reperfusion for 2 weeks (ischemia/reperfusion injury model). EdU (350 μg/100 μl PBS; i.p.) 
treatments were given at every alternate day till day 12. Post 2 weeks of surgery, 
echocardiography was performed, and the hearts were collected for CM isolation and 
culture. f Immunostaining of CMs, against TnI (green) and EdU (Red; indicated by 
arrowhead). Cell nuclei were counterstained with DAPI (blue). g–i Quantification of EdU 
labeling, cell nucleation (Mono-, bi-, multi-), and CM size, showing a significant increase in 
EdU+ CMs and mono-nucleation, while multi-nucleation was decreased in 210-TG hearts 
following I/R injury. N = 4 for all studies. *P < 0.05 vs NTG
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MiR-210 overexpression rescues heart function following MI in adult mice. a Schematic 
representation showing 12 weeks old mice undergoing permanent LAD ligation followed by 
EdU (350 μg/100 μl PBS; i.p.) treatments at every alternate day till day 12. 
Echocardiography (Echo) was performed prior to surgery, and at day 28 following surgery 
(post-MI). Four weeks post-surgery, mice were euthanized, and the hearts were collected for 
histopathology and molecular studies. b Representative images of Masson’s Trichrome 
stained heart sections in NTG and 210-TG following MI, illustrating infarct area (blue). c 
Representative images for echo analysis at baseline and post-MI. d–f Quantification of 
miR-210 fold change expression, infarct size, and heart weight to body weight ratio in 210-
TG and NTG hearts following MI, indicating miR-210 overexpression, decrease in scar size, 
and similar HW/BW ratio in 210-TG as compared to NTG. g–h Echocardiographic 
assessment, and quantification of heart function at baseline and post-MI, showing significant 
restoration of LVEF and LVFS in 210-TG. For all studies N = 9. *P < 0.05 vs NTG
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MiR-210 overexpression promotes CM proliferation in adultmice post MI. a Representative 
immunostained heart sections at peri-infarct zone in 12-week-old mice, post 4 weeks of 
LAD ligation, illustrating TnI (red) and WGA (green) stained CMs. Cell nuclei were 
counterstained with DAPI (blue). b Confocal microscope images of heart sections at the 
peri-infarct region, showing immunostaining for TnI (green) and EdU (red). c 
Representative confocal images of the peri-infarct zone, indicating cardiac specific TnT 
(green) and cell cytokinesis marker Aurora B (red). d–f Quantification of CM area, and EdU 
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and Aurora B labeled CMs at the peri-infarct zone, showing a significant decrease in CM 
size, and a robust increase in EdU and Aurora B+ CMs in 210-TG hearts. g–h Western blots 
representing fold change expression levels of APC, β-catenin, and p16 in NTG and 210-TG 
heart at baseline and post-MI. GAPDH and β-actin were used as loading controls for 
densitometry analysis, indicating downregulation of APC and p16, while β-catenin was 
upregulated in 210-TG hearts. For all studies N = 4. *P < 0.05 vs NTG
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MiR-210 overexpression reduces apoptosis and promotes CM survival in adult mice 
following MI. a Representative confocal images of NTG and 210-TG mice hearts following 
MI, illustrating TnI (green) and TUNEL+ CM (red) at the peri-infarct zone. Cell nuclei were 
counterstained with DAPI (blue). b Quantitative analysis showing a significant decrease in 
apoptotic TUNEL+ CMs in 210-TG hearts. c–d Western blots indicating fold change 
expression levels of Bcl-2 and cleaved caspase-3 to caspase-3 ratio in NTG and 210-TG 
mice heart at baseline and post-MI. GAPDH and β-actin were used as loading controls for 
densitometry, showing upregulation of Bcl-2 and downregulation of caspase-3 level in 210-
TG hearts following MI. For all studies N = 4. *P < 0.05 vs NTG
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MiR-210 overexpression promotes angiogenesis in adult mice post-cardiac injury. a Adult 
mice heart sections at the peri-infarct zone, showing blood vessels (indicated by arrowheads) 
illustrated via outer multilayered smooth muscle actin (SMA) positive cells (green), and 
inner single layered VWF stained endothelial cells (red). b Quantitative analysis of blood 
vessel density at the peri-infarct zone, indicating upregulated angiogenesis in the 210-TG 
heart. c Western blots showing fold change expression of angiogenic factor VEGF in NTG 
and 210-TG hearts at baseline and post-MI (LAD). β-actin was used as loading control for 
densitometry, showing upregulation of VEGF in 210-TG hearts following MI. d 
Representative bright field images for aortic ring assay performed in 12 weeks old NTG and 
210-TG mice, illustrating aortic neovascularization, indicated by microvessel sprouting 
(indicated by arrowheads). NTG mice aorta treated with VEGF (NTGVEGF) was used as 
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positive control. e Quantification of aortic outgrowths/sprouts, showing a significant increase 
in neovascularization in 210-TG and NTGVEGF groups as compared to NTG. For all studies 
N = 4. *P < 0.05 vs NTG
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